More than three migraine attacks per month that were not MAM attacks

Coronary artery disease including coronary vasospasm

Significant cerebrovascular disease including basilar or hemiplegic migraine

Uncontrolled hypertension

Severe hepatic or renal insufficiency

More than 15 headache days per month

Any other condition or serious illness which would interfere with optimal participation in the study

History of clinically relevant allergy, including that to frovatriptan or other triptans

Pregnant or breast feeding or intending to become pregnant or to breast-feed during study period

Participated in other frovatriptan menstrual migraine prevention studies

Use of another investigation drug within 30 days or 5 half-lives (whichever is longer) before the screening visit

A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine